Derazantinib, an oral fibroblast growth factor receptor inhibitor, in phase-2 clinical development, shows anti-angiogenic activity in pre-clinical models-MedSci.cn

Derazantinib, an oral fibroblast growth factor receptor inhibitor, in phase-2 clinical development, shows anti-angiogenic activity in pre-clinical models

Mcsheehy, P; Boult, J; Robinson, S; Bachmann, F; El Shemerly, M; Kellenberger, L; Lane, H

EUROPEAN JOURNAL OF CANCER, 2020; 138 (): S25

科室
- - 订阅+
  - 更多科室
工具
服务